2006
DOI: 10.1159/000091436
|View full text |Cite
|
Sign up to set email alerts
|

The Neurofilament Heavy Chain (NfH<sup>SMI35</sup>) in the Cerebrospinal Fluid Diagnosis of Alzheimer’s Disease

Abstract: Background/Aims: Attempting to improve the cerebrospinal fluid (CSF) diagnosis of Alzheimer’s disease (AD), the neurofilament heavy chain isoform, NfHSMI35 was compared to other CSF markers [total tau, phospho-tau, amyloid beta 1–42 (Aβ42), the ratio of amyloid beta fragments Aβ42/Aβ40 (Aβ ratio)]. Methods: CSF levels were determined in patients with AD (n = 109), mild cognitive impairment (MCI, n = 25), frontotemporal dementia (n = 15), vascular dementia (VD, n = 41), and controls (n = 58). Results… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

3
46
1

Year Published

2007
2007
2021
2021

Publication Types

Select...
8
1
1

Relationship

3
7

Authors

Journals

citations
Cited by 59 publications
(50 citation statements)
references
References 54 publications
3
46
1
Order By: Relevance
“…The gradient agrees with the model for brain-derived proteins described by Reiber. The levels of NfH did not correlate with age in any of the groups tested, agreeing with previous reports [22]. The lumbar levels of NfH were almost 18 times higher than the cisternal levels.…”
Section: Discussionsupporting
confidence: 92%
“…The gradient agrees with the model for brain-derived proteins described by Reiber. The levels of NfH did not correlate with age in any of the groups tested, agreeing with previous reports [22]. The lumbar levels of NfH were almost 18 times higher than the cisternal levels.…”
Section: Discussionsupporting
confidence: 92%
“…Thus, the CSF concentration of NF-L mirrors the degree of acute axonal degradation. Elevated concentrations of neurofilament subunits have been described in many neurological diseases including Alzheimer's disease (Sjogren et al, 2000;Brettschneider et al, 2006), vascular dementia (Bjerke et al, 2009), amyotrophic lateral sclerosis (Zetterberg et al, 2007;Lu et al, 2012), and multiple sclerosis (Salzer et al, 2010). In multiple sclerosis, the CSF concentration of NF-L is downregulated by treatment with the anti-inflammatory drug natalizumab, indirectly implicating that increased CSF NF-L reflects inflammatory-mediated axonal damage (Gunnarsson et al, 2011).…”
Section: Discussionmentioning
confidence: 99%
“…Another study found increased levels of CSF NfL in patients with AD, FTD and vascular dementia relative to control subjects, although the levels were significantly higher in FTD and vascular dementia than in AD, with very high levels of CSF NfL in 4 out of 5 FTD patients [27] . Only 1 recent study has investigated CSF t-NfH levels in AD and other dementias [28] . In this study, the CSF t-NfH levels were higher in AD and vascular dementia patients than in controls, whereas no differences with other dementias were found, although only 15 FTLD patients were included.…”
Section: Discussionmentioning
confidence: 99%